IM Cannabis (NASDAQ:IMCC) versus Harrow (NASDAQ:HROW) Head to Head Survey

IM Cannabis (NASDAQ:IMCC) and Harrow (NASDAQ:HROW) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and recommmendations for IM Cannabis and Harrow, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1	0	0	0	1.00
Harrow	1	2	7	0	2.60

Harrow has a consensus price target of $66.17, indicating a potential upside of 134.30%. Given Harrow’s stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than IM Cannabis.

Insider and Institutional Ownership

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

IM Cannabis has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Profitability

This table compares IM Cannabis and Harrow’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	N/A	-58.32%
Harrow	-13.51%	-38.00%	-3.37%

Earnings and Valuation

This table compares IM Cannabis and Harrow”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17 million	0.01	-$8.10 million	($60.66)	-0.02
Harrow	$272.30 million	3.89	-$5.14 million	($1.00)	-28.24

Harrow has higher revenue and earnings than IM Cannabis. Harrow is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Harrow beats IM Cannabis on 11 of the 13 factors compared between the two stocks.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.